全文获取类型
收费全文 | 12706篇 |
免费 | 907篇 |
国内免费 | 45篇 |
专业分类
耳鼻咽喉 | 95篇 |
儿科学 | 338篇 |
妇产科学 | 176篇 |
基础医学 | 1560篇 |
口腔科学 | 265篇 |
临床医学 | 1421篇 |
内科学 | 2955篇 |
皮肤病学 | 114篇 |
神经病学 | 1122篇 |
特种医学 | 587篇 |
外科学 | 2020篇 |
综合类 | 116篇 |
现状与发展 | 1篇 |
一般理论 | 6篇 |
预防医学 | 946篇 |
眼科学 | 226篇 |
药学 | 817篇 |
中国医学 | 10篇 |
肿瘤学 | 883篇 |
出版年
2021年 | 195篇 |
2020年 | 114篇 |
2019年 | 196篇 |
2018年 | 217篇 |
2017年 | 152篇 |
2016年 | 150篇 |
2015年 | 194篇 |
2014年 | 299篇 |
2013年 | 531篇 |
2012年 | 719篇 |
2011年 | 765篇 |
2010年 | 428篇 |
2009年 | 423篇 |
2008年 | 734篇 |
2007年 | 778篇 |
2006年 | 764篇 |
2005年 | 741篇 |
2004年 | 691篇 |
2003年 | 689篇 |
2002年 | 638篇 |
2001年 | 223篇 |
2000年 | 207篇 |
1999年 | 213篇 |
1998年 | 152篇 |
1997年 | 151篇 |
1996年 | 127篇 |
1995年 | 112篇 |
1994年 | 101篇 |
1993年 | 95篇 |
1992年 | 143篇 |
1991年 | 118篇 |
1990年 | 130篇 |
1989年 | 137篇 |
1988年 | 120篇 |
1987年 | 116篇 |
1986年 | 118篇 |
1985年 | 120篇 |
1984年 | 106篇 |
1983年 | 93篇 |
1982年 | 102篇 |
1981年 | 114篇 |
1980年 | 92篇 |
1979年 | 123篇 |
1978年 | 76篇 |
1977年 | 92篇 |
1976年 | 85篇 |
1975年 | 61篇 |
1974年 | 62篇 |
1973年 | 63篇 |
1972年 | 57篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Deitelzweig Steve Luo Xuemei Nguyen Jennifer L. Malhotra Deepa Emir Birol Russ Cristina Li Xiaoyan Lee Theodore C. Ferri Mauricio Wiederkehr Danny Reimbaeva Maya Barnes Geoffrey D. Piazza Gregory 《Journal of thrombosis and thrombolysis》2022,54(4):696-696
Journal of Thrombosis and Thrombolysis - 相似文献
2.
3.
4.
5.
6.
Theodore C. Bania MD MS Tom Ashar MD Gregory Press MD Patricia M. Carey MD 《Academic emergency medicine》2003,10(7):697-704
Long-term daily use of gamma-hydroxybutyrate (GHB) and related compounds has recently been associated with a withdrawal syndrome. To the best of the authors' knowledge, there are currently no animal models of GHB withdrawal. OBJECTIVES: The authors studied and described the effect of chronic dosing of GHB (3-6 days) on tolerance and withdrawal in a rat model. METHODS: Rats were administered GHB every three hours via intraperitoneal catheter. Groups of rats (2 per group) were dosed with GHB for either 3 (24 doses), 4 (32 doses), 5 (40 doses), or 6 (48 doses) days. The GHB dose was 0.25 g/kg for doses 1-8, 0.75 g/kg for doses 9-12, 1 g/kg for doses 13-16, 1.25 g/kg for doses 17-24, 1.5 g/kg for doses 25-32, 1.75 g/kg for doses 33-40, and 2 g/kg for doses 41-48. Following the last dose of GHB, the rats were scored using a 16-point ethanol intoxication-withdrawal scale rating spontaneous behaviors, response to handling, grooming, and neurological signs. Lower scores indicate intoxication, while higher scores indicate withdrawal. Scores were recorded at hours 0, 1, 2, 3, 4, 5, 6, 9, 12, and 24. RESULTS: Tolerance: Rats dosed with GHB for more days were less intoxicated one hour after their last GHB dose despite receiving higher doses. WITHDRAWAL: The scores for all rats dosed with GHB increased at hours 4 (p = 0.028), 5 (p = 0.037), 6 (p = 0.007), and 9 (p = 0.024) after the last dose, indicating withdrawal. The scores demonstrated a linear increase dependent upon the number of days of GHB dosing at hours 3 (p < 0.000), 4 (p = 0.004), 5 (p = 0.002), and 12 (p = 0.039) as well as prior to the last dose at hour 0 (p = 0.000). No rats developed seizures. CONCLUSIONS: Tolerance and mild withdrawal in rats can be induced by administering intraperitoneal GHB every three hours for 3-6 days. More prolonged dosing and higher doses of GHB may be necessary to induce severe withdrawal. 相似文献
7.
For many parents stopping life-sustaining medical treatment on their dying infant is psychologically impossible. Dostoevsky's insights into human behavior, particularly the fact that individuals do not want the anxiety and guilt associated with responsibility for making difficult decisions, might change the way physicians approach parents for permission to withdraw life-prolonging medical interventions on dying infants. 相似文献
8.
9.
10.
Confounders contributing to the reported associations of coffee or caffeine with disease 总被引:2,自引:0,他引:2
G B Schreiber M Robins C E Maffeo M N Masters A P Bond D Morganstein 《Preventive medicine》1988,17(3):295-309
The role of caffeine or coffee in causing or promoting the incidence of serious disease is equivocal. Two design factors may account for the discrepancies in reported findings on the effects of coffee drinking: (a) imprecision of measurement and (b) confounding variables. A study of 2,714 white U.S. adults disclosed that, of 32 risk factors analyzed by linear and logistic regression, only sex and cigarette smoking were found to be important potential confounders of caffeine and coffee intake. Partial R2 values of the other 30 risk factors were relatively small and were inconsistent for each sex. It is unlikely that any of these factors could explain any of the reported associations between caffeine or coffee consumption and certain diseases. However, certain weak associations with caffeine or coffee intake should be included in the study design when they are known to be risk factors of a disease under investigation. These factors for men are dietary fat intake, vitamin C intake, and body mass index; and for women are vitamin use, alcohol intake, stress, and perceived health status. 相似文献